DRL to expand capacity of manufacturing units in Telangana

Image
Press Trust of India Hyderabad
Last Updated : Feb 04 2015 | 6:10 PM IST
Drug maker Dr Reddy's Laboratories is set to expand the capacity of three of its bulk drugs and intermediates manufacturing plants located in Telangana, with a combined investment of Rs 82 crore.
The company has approached the Ministry of Environment and Forests for necessary approvals for expanding the combined capacity of three facilities to over 142 tonnes per month from existing 41 tonnes, according to minutes of the meeting held last month by Expert Appraisal Committee under MoEF.
Dr Reddy's Laboratories, Chemical Techops-II has proposed for expansion of bulk drugs and intermediates manufacturing unit (from 21.9 TPM to 68.76 TPM) in Telangana's Medak district.
It proposes to expand the API manufacturing capacity from 21.9 TPM to 68.76 TPM in an area of 16.81 acres (existing 13.27 acres & additional proposed 3.54 acres), EAC said.
"The capital cost for expansion is Rs 40 crore, towards modernisation of zero liquid discharge facility, debottlenecking..." EAC said in case of one of the three plants.
The capital cost for expansion of other two plants would be Rs 30 crore and Rs 12 crore while the capacities would go up to 45.5 TPM and 28.1 TPM, respectively, for both the plants, it further said.
When contacted, a Dr Reddy's spokesperson said the company planned to spend Rs 1,000 crore towards capex during the current financial year.
"We have spent approx Rs 675 crore during the past three quarters in FY15. Full year FY15 plan may be around Rs 1,000 crore or so. FY16 numbers cannot be communicated at the moment," the DRL official told PTI.
The manufacturing capacities of some of the fast moving drugs such as Omeprazole, Atorvastatin, Ciprofloxacin HCL, Fondaparinux Sodium, Metoprolol Succinate, Clopidogrel Bisulphate and Fexofenadine Hydrochloride are set to go up considerably once the expansion takes place, the EAC note added.
Shares of Dr Reddy's were trading at Rs 3,097.90 apiece, up 0.21 per cent, on BSE even as the benchmark Sensex was down by 0.58 per cent at 1530 hrs.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 04 2015 | 6:10 PM IST

Next Story